[go: up one dir, main page]

BE1000253A3 - Preparation pharmaceutique stable contenant un facteur de stimulation des colonies de granulocytes et procede pour la produire. - Google Patents

Preparation pharmaceutique stable contenant un facteur de stimulation des colonies de granulocytes et procede pour la produire. Download PDF

Info

Publication number
BE1000253A3
BE1000253A3 BE8700787A BE8700787A BE1000253A3 BE 1000253 A3 BE1000253 A3 BE 1000253A3 BE 8700787 A BE8700787 A BE 8700787A BE 8700787 A BE8700787 A BE 8700787A BE 1000253 A3 BE1000253 A3 BE 1000253A3
Authority
BE
Belgium
Prior art keywords
sep
factor
pharmaceutical preparation
acid
preparation containing
Prior art date
Application number
BE8700787A
Other languages
English (en)
French (fr)
Inventor
Machida Minoru
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of BE1000253A3 publication Critical patent/BE1000253A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BE8700787A 1986-07-18 1987-07-15 Preparation pharmaceutique stable contenant un facteur de stimulation des colonies de granulocytes et procede pour la produire. BE1000253A3 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP16948686 1986-07-18
JP16948886 1986-07-18
JP16948786 1986-07-18
JP16948986 1986-07-18

Publications (1)

Publication Number Publication Date
BE1000253A3 true BE1000253A3 (fr) 1988-09-27

Family

ID=27474266

Family Applications (1)

Application Number Title Priority Date Filing Date
BE8700787A BE1000253A3 (fr) 1986-07-18 1987-07-15 Preparation pharmaceutique stable contenant un facteur de stimulation des colonies de granulocytes et procede pour la produire.

Country Status (24)

Country Link
KR (1) KR930004597B1 (da)
CN (1) CN1033738C (da)
AT (1) AT402259B (da)
AU (1) AU611856B2 (da)
BE (1) BE1000253A3 (da)
CA (1) CA1297007C (da)
CH (1) CH671157A5 (da)
DE (1) DE3723781C2 (da)
DK (1) DK171308B1 (da)
ES (1) ES2010226A6 (da)
FR (1) FR2601591B1 (da)
GB (1) GB2193631B (da)
GR (1) GR871067B (da)
HK (1) HK64893A (da)
HU (1) HU198627B (da)
IE (1) IE60290B1 (da)
IL (1) IL83220A (da)
IT (1) IT1218927B (da)
NL (1) NL192917C (da)
NO (1) NO171828C (da)
PT (1) PT85343B (da)
SE (1) SE503312C2 (da)
SG (1) SG64393G (da)
YU (1) YU47543B (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
NO179479C (no) * 1988-03-11 1996-10-16 Teikoku Seiyaku Kk Fremgangsmåte for fremstilling av et intravaginalt farmasöytisk preparat
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
EP0459516A1 (en) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2693907B1 (fr) * 1992-07-23 1994-09-02 Rhone Poulenc Rorer Sa Procédé d'administration de solutions de facteur de stimulation des colonies granulocytaires.
EP0582932A1 (de) * 1992-08-11 1994-02-16 F. Hoffmann-La Roche Ag Therapeutisches System zur parenteralen Verabreichung von hämatopoetischen Wachstumsfaktoren
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU695129B2 (en) * 1995-02-06 1998-08-06 Genetics Institute, Llc Formulations for IL-12
TW434020B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions
TW434021B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
EP1060746A4 (en) * 1998-03-06 2002-06-19 Chugai Pharmaceutical Co Ltd PROTEIN-FREE PREPARATIONS
US6979442B1 (en) * 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
WO2001017542A1 (fr) * 1999-09-08 2001-03-15 Chugai Seiyaku Kabushiki Kaisha Preparation de solution de proteines et procede de stabilisation associe
TR200401573T4 (tr) * 2000-02-29 2004-08-23 Pfizer Products Inc. Stabilize edilmiş granülosit koloni uyarıcı faktör
WO2001064241A1 (fr) * 2000-02-29 2001-09-07 Chugai Seiyaku Kabushiki Kaisha Preparations stabilisees a long terme
CA2747325A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
CA2420850A1 (en) 2000-09-01 2003-02-28 Chugai Seiyaku Kabushiki Kaisha Solution formulations having long-term stability
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
US7423007B2 (en) 2002-08-27 2008-09-09 Biokine Therapeutics Ltd. Cxcr4 antagonist and use thereof
EP1598074B1 (en) 2003-02-28 2019-01-02 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
EP2104507A4 (en) 2006-12-21 2011-05-25 Biokine Therapeutics Ltd T-140 PEPTIDE ANALOGUE WITH CXCR4 SUPERAGONIST ACTIVITY FOR CANCER THERAPY
WO2010092571A2 (en) 2009-02-11 2010-08-19 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
CN102740840A (zh) * 2010-01-19 2012-10-17 韩美科学株式会社 长效g-csf缀合物的液体制剂
EP2399572A1 (en) 2010-06-22 2011-12-28 Sandoz AG Long-term storage of non-glycosylated recombinant human G-CSF
EP3943098A3 (en) 2015-07-16 2022-05-11 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
BR112018016924A2 (pt) 2016-02-23 2019-01-02 Biokine Therapeutics Ltd método de seleção de regime de tratamento para indivíduo que tem leucemia mieloide aguda (lma), método de maximização de resposta ao tratamento de leucemia mieloide aguda (lma), método de tratamento de lma, antagonista de cxcr4 e agente quimioterápico no tratamento de lma
WO2018138267A1 (en) 2017-01-27 2018-08-02 Cinfa Biotech S.L. Method for determining the efficacy of a g-csf containing composition
PL3797752T3 (pl) * 2018-05-21 2024-10-28 Chugai Seiyaku Kabushiki Kaisha Preparat liofilizowany szczelnie zamknięty w pojemniku szklanym

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2016477A (en) * 1978-03-20 1979-09-26 Green Cross Corp HGI-glycoprotein and isolation thereof
EP0098110A2 (en) * 1982-06-24 1984-01-11 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
EP0162332A1 (en) * 1984-04-26 1985-11-27 Suntory Limited Preparation containing stabilized polypeptide having gamma-interferon activity
EP0178576A1 (en) * 1984-10-09 1986-04-23 Chugai Seiyaku Kabushiki Kaisha Method and composition for preventing the adsorption of a medicine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652636A1 (de) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
ATE80894T1 (de) * 1985-02-05 1992-10-15 Cetus Oncology Corp Reinigung des natuerlichen kolonie-stimulierenden faktors-1.
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPH0618778B2 (ja) * 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2016477A (en) * 1978-03-20 1979-09-26 Green Cross Corp HGI-glycoprotein and isolation thereof
EP0098110A2 (en) * 1982-06-24 1984-01-11 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
EP0162332A1 (en) * 1984-04-26 1985-11-27 Suntory Limited Preparation containing stabilized polypeptide having gamma-interferon activity
EP0178576A1 (en) * 1984-10-09 1986-04-23 Chugai Seiyaku Kabushiki Kaisha Method and composition for preventing the adsorption of a medicine

Also Published As

Publication number Publication date
YU47543B (sh) 1995-10-03
FR2601591A1 (fr) 1988-01-22
SE503312C2 (sv) 1996-05-13
FR2601591B1 (fr) 1991-04-26
DK171308B1 (da) 1996-09-02
IL83220A0 (en) 1987-12-31
KR930004597B1 (ko) 1993-06-01
CA1297007C (en) 1992-03-10
IE60290B1 (en) 1994-06-29
NL8701640A (nl) 1988-02-16
IT8767594A0 (it) 1987-07-10
PT85343B (pt) 1990-04-30
CH671157A5 (de) 1989-08-15
NO872966D0 (no) 1987-07-16
ES2010226A6 (es) 1989-11-01
HK64893A (en) 1993-07-16
YU134287A (en) 1989-06-30
NL192917C (nl) 1998-05-07
AU611856B2 (en) 1991-06-27
GR871067B (en) 1987-11-19
DK368387D0 (da) 1987-07-15
HU198627B (en) 1989-11-28
AU7566587A (en) 1988-01-21
NL192917B (nl) 1998-01-05
AT402259B (de) 1997-03-25
IE871933L (en) 1988-01-18
GB2193631A (en) 1988-02-17
GB8716904D0 (en) 1987-08-26
ATA177587A (de) 1996-08-15
DE3723781A1 (de) 1988-01-21
DK368387A (da) 1988-01-19
KR880001297A (ko) 1988-04-22
NO872966L (no) 1988-01-19
CN87104963A (zh) 1988-02-24
DE3723781C2 (de) 1999-09-02
NO171828B (no) 1993-02-01
SE8702907D0 (sv) 1987-07-17
IT1218927B (it) 1990-04-24
HUT44941A (en) 1988-05-30
IL83220A (en) 1993-01-31
SE8702907L (sv) 1988-01-19
SG64393G (en) 1993-08-06
PT85343A (en) 1987-08-01
GB2193631B (en) 1990-11-21
CN1033738C (zh) 1997-01-08
NO171828C (no) 1993-05-12

Similar Documents

Publication Publication Date Title
BE1000253A3 (fr) Preparation pharmaceutique stable contenant un facteur de stimulation des colonies de granulocytes et procede pour la produire.
JP7150804B2 (ja) プラミノーゲンを含む医薬組成物及びその使用
US5919443A (en) Stable lyophilized pharmaceutical preparations of G-CSF
JP3530300B2 (ja) 安定なトランスグルタミナーゼ製剤およびそれらを製造する方法
JPH0552808B2 (da)
CH695185A5 (fr) Compositions pharmaceutiques injectables contenant de la piperacilline et du tazobactame et procede pour leur production.
AU738413B2 (en) Human growth hormone-containing aqueous pharmaceutical composition
FR2591485A1 (fr) Compositions stabilisees contenant l'activateur du plasminogene du tissu humain.
AU3275199A (en) Protein-free preparations
KR100807650B1 (ko) Ｎ-[ｏ-(ｐ-피발로일옥시벤젠술포닐아미노)벤조일]글리신·모노나트륨염·4수화물의 동결 건조 제제 및 그 제조 방법
JPS63146826A (ja) 安定な顆粒球コロニ−刺激因子含有製剤
NZ234341A (en) Pharmaceutical surfactant suspensions for treatment of respiratory diseases
AU5409201A (en) Solution of N-(O-(p-pivaloyloxy benzene sulfonylamino) benzoyl)glycine monosodium salt tetra-hydrate and drug product thereof
JPS63146827A (ja) 安定な顆粒球コロニ−刺激因子含有製剤
HU218103B (hu) Nem-glikozilezett, rekombináns humán interleukin-2 redukált alakját tartalmazó, stabilizált gyógyászati készítmény és eljárás előállítására
JPS63152326A (ja) 安定な顆粒球コロニ−刺激因子含有製剤
WO2023233277A1 (en) Lyophilized pharmaceutical compositions of copper histidinate
CN117062597A (zh) 稳定的吲哚菁绿制剂
JPH07291865A (ja) プロスタグランジンｅ▲１▼の安定化組成物
UA50811C2 (uk) Ліофілізована композиція морфогенетичного фактора кістки, спосіб одержання ліофілізованої композиції морфогенетичного фактора кістки
JPH06166624A (ja) 血液保存剤および血液保存方法

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: *CHUGAI SEIYAKU K.K.

Effective date: 20070715